Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 2

Key Updates in the Treatment of ES-SCLC

,

Panelists discuss how recent real-world data comparing atezolizumab and durvalumab in extensive-stage non–small cell lung cancer (ES-NSCLC) informs treatment selection, though direct comparisons remain limited. Lurbinectedin is a key second-line option, with emerging combination strategies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Expert Insights on Recent Advancements in LS-SCLC
    Now Viewing
    EP. 2: Key Updates in the Treatment of ES-SCLC
    EP. 3: Expert Perspectives on Tarlatamab in ES-SCLC
    EP. 4: Looking Ahead in SCLC: ADCs and Other Novel Agents
    EP. 5: Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC
    EP. 6: Personalizing Adjuvant Targeted Therapy in Early-Stage NSCLC
    EP. 7: New Targeted Approaches in Unresectable Early-Stage NSCL
    EP. 8: Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC
    EP. 9: Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond
    EP. 10: Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations
    EP. 11: Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations
    EP. 12: Tailoring Immunotherapy Strategies for Advanced NSCLC

    Video content above is prompted by the following:

    • What are your perceptions on recent retrospective real-world data comparing atezolizumab and durvalumab, and how do you incorporate these findings into your treatment decision making in patients with ES-NSCLC?
    • Briefly discuss the role of lurbinectedin in the second-line treatment setting. How are you incorporating lurbinectedin into your treatment approach, and what is the potential role of novel lurbinectedin-based combination strategies?
    x